<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01076088</url>
  </required_header>
  <id_info>
    <org_study_id>0431-121</org_study_id>
    <secondary_id>2010_514</secondary_id>
    <nct_id>NCT01076088</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121)</brief_title>
  <official_title>A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial in China to Study the Safety and Efficacy of Co-administration of Sitagliptin and Metformin in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the efficacy and safety of initial treatment with sitagliptin and
      metformin in patients with type 2 diabetes mellitus in China. The primary hypothesis is that
      after 24 weeks, initial co-administration treatment with sitagliptin and metformin provided
      greater reduction in hemoglobin A1C (A1C) compared to initial treatment with sitagliptin
      alone and with metformin alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 15, 2010</start_date>
  <completion_date type="Actual">December 24, 2012</completion_date>
  <primary_completion_date type="Actual">December 24, 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Hemoglobin A1C (A1C) at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 2-hour Post Meal Glucose (2-h PMG) at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Change from baseline in 2-h PMG at Week 24 is defined as Week 24 2-h PMG minus Week 0 2-h PMG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Change from baseline in FPG at Week 24 is defined as Week 24 FPG minus Week 0 FPG.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">744</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Sitagliptin 50 mg + metformin 500 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sitagliptin 50 mg and metformin 500 mg twice a day for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin 50 mg + metformin 850 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sitagliptin 50 mg and metformin 850 mg twice a day for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin 500 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin 500 mg twice daily for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin 850 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin 850 mg twice daily for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sitagliptin 100 mg once daily for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo tablets for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin 50 mg</intervention_name>
    <description>Sitagliptin 50 mg tablet twice a day, prior to the morning and evening meal, for 24 weeks.</description>
    <arm_group_label>Sitagliptin 50 mg + metformin 500 mg</arm_group_label>
    <arm_group_label>Sitagliptin 50 mg + metformin 850 mg</arm_group_label>
    <other_name>Januvia®, Tesavel®, Xelevia®, Ristaben®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin 500 mg</intervention_name>
    <description>Metformin 500 mg tablet twice daily, prior to the morning and evening meal, for 24 weeks.</description>
    <arm_group_label>Sitagliptin 50 mg + metformin 500 mg</arm_group_label>
    <arm_group_label>Metformin 500 mg</arm_group_label>
    <other_name>Fortamet®, Glucophage®, Glucophage® XR, Glumetza®, Riomet®, Metgluco®, Glycoran®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin 100 mg</intervention_name>
    <description>Sitagliptin 100 mg once daily for 24 weeks.</description>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
    <other_name>Januvia®, Tesavel®, Xelevia®, Ristaben®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo tablets to sitagliptin or metformin for 24 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin 850 mg</intervention_name>
    <description>Metformin 850 mg tablet twice daily, prior to the morning and evening meal, for 24 weeks.</description>
    <arm_group_label>Sitagliptin 50 mg + metformin 850 mg</arm_group_label>
    <arm_group_label>Metformin 850 mg</arm_group_label>
    <other_name>Fortamet®, Glucophage®, Glucophage® XR, Glumetza®, Riomet®, Metgluco®, Glycoran®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  has type 2 diabetes mellitus

          -  is male, a female who cannot have children, or a female who agrees to use birth
             control during the study

          -  is not on an antihyperglycemic agent (AHA) (hemoglobin A1c [A1C] 7.5-11.0%) or on oral
             single AHA (A1C 7.0-10.5%) or low-dose AHA combination therapy (A1C 7.0-10.0%)

        Exclusion Criteria:

          -  Patient has type 1 diabetes mellitus or ketoacidosis

          -  Patient is taking a dipeptidyl peptidase-4 (DPP-4) inhibitor (such as sitagliptin)

          -  Patient is on a weight loss program not in the maintenance phase or on a weight loss
             medication

          -  Patient has a history of liver disease, heart failure, heart disease, stroke, high
             blood pressure, blood disorders, or cancer

          -  Patient is HIV positive

          -  Patient is pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>78 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>China</country>
  </removed_countries>
  <results_reference>
    <citation>Ji L, Han P, Wang X, Liu J, Zheng S, Jou YM, O'Neill EA, Golm GT, Engel SS, Kaufman KD, Shankar RR. Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co-administered to Chinese patients with type 2 diabetes mellitus. J Diabetes Investig. 2016 Sep;7(5):727-36. doi: 10.1111/jdi.12511. Epub 2016 May 19.</citation>
    <PMID>27181998</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2010</study_first_submitted>
  <study_first_submitted_qc>February 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2010</study_first_posted>
  <results_first_submitted>December 17, 2013</results_first_submitted>
  <results_first_submitted_qc>December 17, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 6, 2014</results_first_posted>
  <last_update_submitted>April 27, 2017</last_update_submitted>
  <last_update_submitted_qc>April 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>In total, 744 participants were randomized to treatment. Of these 744 participants, 1 participant, assigned to the placebo group, did not receive study medication. This participant was not included in the safety analyses.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sitagliptin 50 mg + Metformin 500 mg</title>
          <description>Sitagliptin 50 mg twice daily + metformin 500 mg twice daily</description>
        </group>
        <group group_id="P2">
          <title>Sitagliptin 50 mg + Metformin 850 mg</title>
          <description>Sitagliptin 50 mg twice daily + metformin 850 mg twice daily</description>
        </group>
        <group group_id="P3">
          <title>Metformin 500 mg</title>
          <description>Metformin 500 mg twice daily</description>
        </group>
        <group group_id="P4">
          <title>Metformin 850</title>
          <description>Metformin 850 mg twice daily</description>
        </group>
        <group group_id="P5">
          <title>Sitagliptin 100 mg</title>
          <description>Sitagliptin 100 mg once daily</description>
        </group>
        <group group_id="P6">
          <title>Placebo</title>
          <description>Matching placebo to sitagliptin and/or metformin. Population includes 1 participant who did not receive any study medication.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="122"/>
                <participants group_id="P2" count="125"/>
                <participants group_id="P3" count="126"/>
                <participants group_id="P4" count="124"/>
                <participants group_id="P5" count="120"/>
                <participants group_id="P6" count="127"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="107"/>
                <participants group_id="P3" count="109"/>
                <participants group_id="P4" count="109"/>
                <participants group_id="P5" count="104"/>
                <participants group_id="P6" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other protocol specified criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sitagliptin 50 mg + Metformin 500 mg</title>
          <description>Sitagliptin 50 mg twice daily + metformin 500 mg twice daily</description>
        </group>
        <group group_id="B2">
          <title>Sitagliptin 50 mg + Metformin 850 mg</title>
          <description>Sitagliptin 50 mg twice daily + metformin 850 mg twice daily</description>
        </group>
        <group group_id="B3">
          <title>Metformin 500 mg</title>
          <description>Metformin 500 mg twice daily</description>
        </group>
        <group group_id="B4">
          <title>Metformin 850</title>
          <description>Metformin 850 mg twice daily</description>
        </group>
        <group group_id="B5">
          <title>Sitagliptin 100 mg</title>
          <description>Sitagliptin 100 mg once daily</description>
        </group>
        <group group_id="B6">
          <title>Placebo</title>
          <description>Matching placebo to sitagliptin and/or metformin. Population includes 1 participant who did not receive any study medication.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="122"/>
            <count group_id="B2" value="125"/>
            <count group_id="B3" value="126"/>
            <count group_id="B4" value="124"/>
            <count group_id="B5" value="120"/>
            <count group_id="B6" value="127"/>
            <count group_id="B7" value="744"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.6" spread="11.3"/>
                    <measurement group_id="B2" value="52.4" spread="9.3"/>
                    <measurement group_id="B3" value="52.6" spread="9.5"/>
                    <measurement group_id="B4" value="53.0" spread="10.3"/>
                    <measurement group_id="B5" value="51.7" spread="10.2"/>
                    <measurement group_id="B6" value="53.6" spread="9.7"/>
                    <measurement group_id="B7" value="52.7" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="46"/>
                    <measurement group_id="B6" value="40"/>
                    <measurement group_id="B7" value="287"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="75"/>
                    <measurement group_id="B5" value="74"/>
                    <measurement group_id="B6" value="87"/>
                    <measurement group_id="B7" value="457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1c (A1C)</title>
          <units>Percent of glycosylated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.46" spread="0.97"/>
                    <measurement group_id="B2" value="8.66" spread="0.95"/>
                    <measurement group_id="B3" value="8.69" spread="0.99"/>
                    <measurement group_id="B4" value="8.67" spread="1.08"/>
                    <measurement group_id="B5" value="8.74" spread="1.14"/>
                    <measurement group_id="B6" value="8.97" spread="1.05"/>
                    <measurement group_id="B7" value="8.70" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting plasma glucose (FPG)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="175.6" spread="40.6"/>
                    <measurement group_id="B2" value="181.9" spread="43.0"/>
                    <measurement group_id="B3" value="184.6" spread="46.8"/>
                    <measurement group_id="B4" value="183.5" spread="47.7"/>
                    <measurement group_id="B5" value="182.5" spread="44.0"/>
                    <measurement group_id="B6" value="185.8" spread="47.3"/>
                    <measurement group_id="B7" value="182.3" spread="45.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>2-hour post meal glucose (2-h PMG)</title>
          <description>Participants with data: sita50/met500, n=121; sita50/met850, n=125; met500, n=125; met850, n=123; sita100, n=119; placebo; n=126; total, n=739</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="292.7" spread="81.2"/>
                    <measurement group_id="B2" value="292.9" spread="68.4"/>
                    <measurement group_id="B3" value="303.2" spread="74.1"/>
                    <measurement group_id="B4" value="298.8" spread="74.6"/>
                    <measurement group_id="B5" value="297.7" spread="74.7"/>
                    <measurement group_id="B6" value="308.3" spread="83.6"/>
                    <measurement group_id="B7" value="299.0" spread="76.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hemoglobin A1C (A1C) at Week 24</title>
        <description>A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Full Analysis Set, all randomized participants except those who: failed to take at least 1 dose of study treatment, lacked all post-randomization data for the A1C subsequent to at least 1 dose of study treatment, or lacked baseline data for the A1C. Last observation carried forward (missing data approach).</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 50 mg + Metformin 500 mg</title>
            <description>Sitagliptin 50 mg twice daily + metformin 500 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin 50 mg + Metformin 850 mg</title>
            <description>Sitagliptin 50 mg twice daily + metformin 850 mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Metformin 500 mg</title>
            <description>Metformin 500 mg twice daily</description>
          </group>
          <group group_id="O4">
            <title>Metformin 850 mg</title>
            <description>Metformin 850 mg twice daily</description>
          </group>
          <group group_id="O5">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg once daily</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Matching placebo to sitagliptin and/or metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin A1C (A1C) at Week 24</title>
          <description>A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.</description>
          <population>Full Analysis Set, all randomized participants except those who: failed to take at least 1 dose of study treatment, lacked all post-randomization data for the A1C subsequent to at least 1 dose of study treatment, or lacked baseline data for the A1C. Last observation carried forward (missing data approach).</population>
          <units>Percent of glycosylated hemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="116"/>
                <count group_id="O4" value="117"/>
                <count group_id="O5" value="113"/>
                <count group_id="O6" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.67" lower_limit="-1.92" upper_limit="-1.43"/>
                    <measurement group_id="O2" value="-1.83" lower_limit="-2.07" upper_limit="-1.58"/>
                    <measurement group_id="O3" value="-1.29" lower_limit="-1.54" upper_limit="-1.04"/>
                    <measurement group_id="O4" value="-1.56" lower_limit="-1.80" upper_limit="-1.32"/>
                    <measurement group_id="O5" value="-0.99" lower_limit="-1.24" upper_limit="-0.75"/>
                    <measurement group_id="O6" value="-0.59" lower_limit="-0.84" upper_limit="-0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.087</p_value>
            <p_value_desc>Pairwise comparison, sitagliptin 50 mg + metformin 850 mg vs. metformin 850 mg. The normality assumption required for validity of ANCOVA was violated due to a biologically implausible extreme outlier. See below for results using robust regression.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline A1C.</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-0.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.58</ci_lower_limit>
            <ci_upper_limit>0.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparison, sitagliptin 50 mg + metformin 850 mg vs. sitagliptin 100 mg. The normality assumption required for validity of ANCOVA was violated due to a biologically implausible extreme outlier. See below for results using robust regression.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.15</ci_lower_limit>
            <ci_upper_limit>-0.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.014</p_value>
            <p_value_desc>Pairwise comparison, sitagliptin 50 mg + metformin 500 mg vs. metformin 500 mg. The normality assumption required for validity of ANCOVA was violated due to a biologically implausible extreme outlier. See below for results using robust regression.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-0.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.69</ci_lower_limit>
            <ci_upper_limit>-0.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparison, sitagliptin 50 mg + metformin 500 mg vs. sitagliptin 100 mg. The normality assumption required for validity of ANCOVA was violated due to a biologically implausible extreme outlier. See below for results using robust regression.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.99</ci_lower_limit>
            <ci_upper_limit>-0.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparison, sitagliptin 50 mg + metformin 850 mg vs. placebo. The normality assumption required for validity of ANCOVA was violated due to a biologically implausible extreme outlier. See below for results using robust regression.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-1.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.55</ci_lower_limit>
            <ci_upper_limit>-0.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparison, metformin 850 mg vs. placebo. The normality assumption required for validity of ANCOVA was violated due to a biologically implausible extreme outlier. See below for results using robust regression.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.28</ci_lower_limit>
            <ci_upper_limit>-0.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparison, sitagliptin 50 mg + metformin 500 mg vs. placebo. The normality assumption required for validity of ANCOVA was violated due to a biologically implausible extreme outlier. See below for results using robust regression.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.39</ci_lower_limit>
            <ci_upper_limit>-0.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparison, metformin 500 mg vs. placebo. The normality assumption required for validity of ANCOVA was violated due to a biologically implausible extreme outlier. See below for results using robust regression.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-0.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.01</ci_lower_limit>
            <ci_upper_limit>-0.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.011</p_value>
            <p_value_desc>Pairwise comparison, sitagliptin 100 mg vs. placebo. The normality assumption required for validity of ANCOVA was violated due to a biologically implausible extreme outlier. See below for results using robust regression.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-0.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.71</ci_lower_limit>
            <ci_upper_limit>-0.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <p_value_desc>Pairwise comparison, sitagliptin 50 mg + metformin 850 mg vs. metformin 850 mg. This is a post-hoc analysis using robust regression, a valid method in the presence of outliers.</p_value_desc>
            <method>Regression, Robust</method>
            <method_desc>The Robust Regression model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.</method_desc>
            <param_type>Difference in least squares mean</param_type>
            <param_value>-0.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.62</ci_lower_limit>
            <ci_upper_limit>-0.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparing co-administration with individual components. This is a post-hoc analysis using robust regression, a valid method in the presence of outliers.</p_value_desc>
            <method>Regression, Robust</method>
            <method_desc>The Robust Regression model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.13</ci_lower_limit>
            <ci_upper_limit>-0.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>Comparing co-administration with individual components. This is a post-hoc analysis using robust regression, a valid method in the presence of outliers.</p_value_desc>
            <method>Regression, Robust</method>
            <method_desc>The Robust Regression model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-0.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.63</ci_lower_limit>
            <ci_upper_limit>-0.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparing co-administration with individual components. This is a post-hoc analysis using robust regression, a valid method in the presence of outliers.</p_value_desc>
            <method>Regression, Robust</method>
            <method_desc>The Robust Regression model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-0.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.88</ci_lower_limit>
            <ci_upper_limit>-0.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparing co-administration with individual components. This is a post-hoc analysis using robust regression, a valid method in the presence of outliers.</p_value_desc>
            <method>Regression, Robust</method>
            <method_desc>The Robust Regression model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-1.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.52</ci_lower_limit>
            <ci_upper_limit>-0.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparing co-administration with individual components. This is a post-hoc analysis using robust regression, a valid method in the presence of outliers.</p_value_desc>
            <method>Regression, Robust</method>
            <method_desc>The Robust Regression model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.16</ci_lower_limit>
            <ci_upper_limit>-0.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparing co-administration with individual components. This is a post-hoc analysis using robust regression, a valid method in the presence of outliers.</p_value_desc>
            <method>Regression, Robust</method>
            <method_desc>The Robust Regression model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.26</ci_lower_limit>
            <ci_upper_limit>-0.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparing co-administration with individual components. This is a post-hoc analysis using robust regression, a valid method in the presence of outliers.</p_value_desc>
            <method>Regression, Robust</method>
            <method_desc>The Robust Regression model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.90</ci_lower_limit>
            <ci_upper_limit>-0.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>Comparing co-administration with individual components. This is a post-hoc analysis using robust regression, a valid method in the presence of outliers.</p_value_desc>
            <method>Regression, Robust</method>
            <method_desc>The Robust Regression model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-0.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.65</ci_lower_limit>
            <ci_upper_limit>-0.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 2-hour Post Meal Glucose (2-h PMG) at Week 24</title>
        <description>Change from baseline in 2-h PMG at Week 24 is defined as Week 24 2-h PMG minus Week 0 2-h PMG.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Full Analysis Set, all randomized participants except those who: failed to take at least 1 dose of study treatment, lacked all post-randomization data for 2-h PMG subsequent to at least 1 dose of study treatment, or lacked baseline data for 2-h PMG. Last observation carried forward (missing data approach).</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 50 mg + Metformin 500 mg</title>
            <description>Sitagliptin 50 mg twice daily + metformin 500 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin 50 mg + Metformin 850 mg</title>
            <description>Sitagliptin 50 mg twice daily + metformin 850 mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Metformin 500 mg</title>
            <description>Metformin 500 mg twice daily</description>
          </group>
          <group group_id="O4">
            <title>Metformin 850</title>
            <description>Metformin 850 mg twice daily</description>
          </group>
          <group group_id="O5">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg once daily</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Matching placebo to sitagliptin and/or metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 2-hour Post Meal Glucose (2-h PMG) at Week 24</title>
          <description>Change from baseline in 2-h PMG at Week 24 is defined as Week 24 2-h PMG minus Week 0 2-h PMG.</description>
          <population>Full Analysis Set, all randomized participants except those who: failed to take at least 1 dose of study treatment, lacked all post-randomization data for 2-h PMG subsequent to at least 1 dose of study treatment, or lacked baseline data for 2-h PMG. Last observation carried forward (missing data approach).</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="112"/>
                <count group_id="O4" value="108"/>
                <count group_id="O5" value="107"/>
                <count group_id="O6" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-97.05" lower_limit="-109.01" upper_limit="-85.09"/>
                    <measurement group_id="O2" value="-109.46" lower_limit="-121.47" upper_limit="-97.44"/>
                    <measurement group_id="O3" value="-65.67" lower_limit="-77.76" upper_limit="-53.58"/>
                    <measurement group_id="O4" value="-90.93" lower_limit="-103.04" upper_limit="-78.83"/>
                    <measurement group_id="O5" value="-48.11" lower_limit="-60.37" upper_limit="-35.85"/>
                    <measurement group_id="O6" value="-21.88" lower_limit="-34.33" upper_limit="-9.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <p_value_desc>Pairwise comparison, sitagliptin 50 mg + metformin 850 mg vs. metformin 850 mg.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline 2-H PMG.</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-18.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.75</ci_lower_limit>
            <ci_upper_limit>-3.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparison, sitagliptin 50 mg + metformin 850 mg vs. sitagliptin 100 mg</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline 2-H PMG.</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-61.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-76.61</ci_lower_limit>
            <ci_upper_limit>-46.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparison, sitagliptin 50 mg + metformin 500 mg vs. metformin 500 mg</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline 2-H PMG.</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-31.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-46.49</ci_lower_limit>
            <ci_upper_limit>-16.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparison, sitagliptin 50 mg + metformin 500 mg vs. sitagliptin 100 mg</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline 2-H PMG.</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-48.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-64.21</ci_lower_limit>
            <ci_upper_limit>-33.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparison, sitagliptin 50 mg + metformin 850 mg vs. placebo</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline 2-H PMG.</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-87.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-102.87</ci_lower_limit>
            <ci_upper_limit>-72.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparison, metformin 850 mg vs. placebo</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline 2-H PMG.</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-69.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-84.41</ci_lower_limit>
            <ci_upper_limit>-53.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparison, sitagliptin 50 mg + metformin 500 mg vs. placebo</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline 2-H PMG.</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-75.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-90.47</ci_lower_limit>
            <ci_upper_limit>-59.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparison, metformin 500 mg vs. placebo</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline 2-H PMG.</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-43.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-58.99</ci_lower_limit>
            <ci_upper_limit>-28.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparison, sitagliptin 100 mg vs. placebo</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline 2-H PMG.</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-26.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-41.62</ci_lower_limit>
            <ci_upper_limit>-10.84</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24</title>
        <description>Change from baseline in FPG at Week 24 is defined as Week 24 FPG minus Week 0 FPG.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Full Analysis Set, all randomized participants except those who: failed to take at least 1 dose of study treatment, lacked all post-randomization data for FPG subsequent to at least 1 dose of study treatment, or lacked baseline data for FPG. Last observation carried forward (missing data approach).</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 50 mg + Metformin 500 mg</title>
            <description>Sitagliptin 50 mg twice daily + metformin 500 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin 50 mg + Metformin 850 mg</title>
            <description>Sitagliptin 50 mg twice daily + metformin 850 mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Metformin 500 mg</title>
            <description>Metformin 500 mg twice daily</description>
          </group>
          <group group_id="O4">
            <title>Metformin 850</title>
            <description>Metformin 850 mg twice daily</description>
          </group>
          <group group_id="O5">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg once daily</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Matching placebo to sitagliptin and/or metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24</title>
          <description>Change from baseline in FPG at Week 24 is defined as Week 24 FPG minus Week 0 FPG.</description>
          <population>Full Analysis Set, all randomized participants except those who: failed to take at least 1 dose of study treatment, lacked all post-randomization data for FPG subsequent to at least 1 dose of study treatment, or lacked baseline data for FPG. Last observation carried forward (missing data approach).</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="119"/>
                <count group_id="O4" value="119"/>
                <count group_id="O5" value="114"/>
                <count group_id="O6" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.38" lower_limit="-46.29" upper_limit="-32.47"/>
                    <measurement group_id="O2" value="-47.74" lower_limit="-54.73" upper_limit="-40.75"/>
                    <measurement group_id="O3" value="-33.66" lower_limit="-40.66" upper_limit="-26.66"/>
                    <measurement group_id="O4" value="-39.63" lower_limit="-46.50" upper_limit="-32.76"/>
                    <measurement group_id="O5" value="-21.86" lower_limit="-28.92" upper_limit="-14.80"/>
                    <measurement group_id="O6" value="-11.93" lower_limit="-18.94" upper_limit="-4.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.069</p_value>
            <p_value_desc>Pairwise comparison, sitagliptin 50 mg + metformin 850 mg vs. metformin 850 mg</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline FPG.</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-8.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.86</ci_lower_limit>
            <ci_upper_limit>0.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparison, sitagliptin 50 mg + metformin 850 mg vs. sitagliptin 100 mg</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline FPG.</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-25.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-34.72</ci_lower_limit>
            <ci_upper_limit>-17.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.198</p_value>
            <p_value_desc>Pairwise comparison, sitagliptin 50 mg + metformin 500 mg vs. metformin 500 mg</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline FPG.</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-5.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.44</ci_lower_limit>
            <ci_upper_limit>3.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparison, sitagliptin 50 mg + metformin 500 mg vs. sitagliptin 100 mg</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline FPG.</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-17.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.33</ci_lower_limit>
            <ci_upper_limit>-8.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparison, sitagliptin 50 mg + metformin 850 mg vs. placebo.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline FPG.</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-35.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-44.56</ci_lower_limit>
            <ci_upper_limit>-27.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparison, metformin 850 mg vs. placebo.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline FPG.</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-27.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-36.40</ci_lower_limit>
            <ci_upper_limit>-19.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparison, sitagliptin 50 mg + metformin 500 mg vs. placebo.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline FPG.</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-27.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-36.18</ci_lower_limit>
            <ci_upper_limit>-18.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparison, metformin 500 mg vs. placebo.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline FPG.</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-21.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.42</ci_lower_limit>
            <ci_upper_limit>-13.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.027</p_value>
            <p_value_desc>Pairwise comparison, sitagliptin 100 mg vs. placebo.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline FPG.</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-9.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.72</ci_lower_limit>
            <ci_upper_limit>-1.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>All participants as treated population. Serious and non-serious adverse events (AEs) include and exclude data after rescue therapy, respectively. One event of hypoglycaemia that, per protocol, should have been reported as an AE was not reported as an AE. This event occurred in a participant who had another event of hypoglycaemia that was reported.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sitagliptin 50 mg + Metformin 500 mg</title>
          <description>Sitagliptin 50 mg twice daily + metformin 500 mg twice daily</description>
        </group>
        <group group_id="E2">
          <title>Sitagliptin 50 mg + Metformin 850 mg</title>
          <description>Sitagliptin 50 mg twice daily + metformin 850 mg twice daily</description>
        </group>
        <group group_id="E3">
          <title>Metformin 500 mg</title>
          <description>Metformin 500 mg twice daily</description>
        </group>
        <group group_id="E4">
          <title>Metformin 850</title>
          <description>Metformin 850 mg twice daily</description>
        </group>
        <group group_id="E5">
          <title>Sitagliptin 100 mg</title>
          <description>Sitagliptin 100 mg once daily</description>
        </group>
        <group group_id="E6">
          <title>Placebo</title>
          <description>Matching placebo to sitagliptin and/or metformin. Population excludes 1 participant who did not receive any study medication.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Coagulation time shortened</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="124"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="122"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="125"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E4" events="10" subjects_affected="9" subjects_at_risk="124"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="125"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="124"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="122"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="125"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="124"/>
                <counts group_id="E5" events="7" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President,Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

